Virologisk respons over for APTIVUS/ ritonavir- behandling er vurderet ud fra en tipranavir- relateret mutationsscore baseret på baseline genotype hos patienter, der deltog i RESIST- 1 og RESIST- 2.
Virological response to APTIVUS/ ritonavir therapy has been evaluated using a tipranavir-associated mutation score based on baseline genotype in RESIST-1 and RESIST-2 patients.